Our comprehensive data demonstrate that this intraoperative procedure provides an outstanding evaluation of patients with more aggressive tumors, such as luminal-B, HER-2 positive or triple negative breast cancer as well as patients with highly proliferating tumors. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.